Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D-229 plus paclitaxel versus placebo plus paclitaxel in platinum-resistant recurrent ovarian cancer
CTR20212926Phase 3Active
- Sponsor
- 3D Medicines Inc.
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of batiraxcept in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by 3D Medicines Inc.. Started Apr 2022; status: active.
02
Drugs
batiraxcept
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20212926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212926.